VideosTake a closer look at some of our assays in our calprotectin product line. Learn more about IBDoc® and Quantum Blue®
BÜHLMANN - IBDoc® Swiss Medtech Award 2018
At this year’s SwissMedtech Day, BÜHLMANN was nominated to receive the Swiss Medtech Award for presenting IBDoc® to a Jury of medtech and academic reperesentatives. The jury nominated 3 projects for the Swiss Medtech Award 2018, BÜHLMANN Laboratories AG among them.
IBDoc® Self-care/Point of care Calprotectin Test: Early Value in a District General Hospital
Pearl Avery from Dorset County Hospital shows very interesting data on the clinical validity and ease of use of the IBDoc® calprotectin home test.
Interview Anke Heida, UMCG, ECCO 2017 Poster
Anke Heida from the Groningen Unversity Medical Center explains the poster published at the European Crohn’s and Colitis Congress.
Interview Caroline Bello, CHU Liege, ECCO 2017 Poster
Caroline Bello from the Liège Center Hosptial Universitaire explains the poster published at the European Crohn’s and Colitis Congress.
IBDoc® Interview with Christian Reinhard at UEGW
BÜHLMANN IBDoc® Product Manager discusses recent market experience with the first CE marked calprotectin home test at United European Gastroenterology Week 2016 in Vienna.
IBDoc® - Perspective from a Patient and Nurse
A patient and a nurse share their perspectives and experience with IBDoc® at United European Gastroenterology Week 2016 in Vienna.
IBDoc® Calprotectin Home Test from BÜHLMANN
An overview of IBDoc® as a diagnostic device for the quantitative determination of calprotectin levels in stool samples for use as a Point-of-Care test or Home Test by the patient.
Quantum Blue® Videos
BÜHLMANN Quantum Blue® fCAL Tutorial
Demonstration of CALEX® Cap extraction and quantitative fecal calprotectin measurement using the Quantum Blue® fCAL rapid test technology.
Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO)
Dr. Rentsch from the Alfred Health Melbourne shows very promising data on infliximab management supported by the Quantum Blue® Infliximab rapid test and implications for therapy cost reduction.
New biosimilar of infliximab SB2 can be quantified by IXF-optimized therapeutic drug monitoring
Joana Afonso from the University of Porto presents data that confirms the validated use of the Quantum Blue® Infliximab assay to quantify the new infliximab biosimilar SB2.
Point-of-care infliximab quantification in inflammatory bowel disease in daily practice
Dr. Maria Pia Santos from the Beatriz Angelo Hospital presents data on an easy integration of the Quantum Blue® TDM rapid test in clinical routine.
Using point of care testing for infliximab and fecal calprotectin in IBD patients with secondary LOR
Dr. Afif from McGill presents a pilot study for the Quantum Blue® Infliximab rapid test application in loss of response patients.
Scientific Poster Quantum Blue® Infliximab
Thomas Schuster, PhD, presents his poster at the 11th ECCO congress about a new rapid test to measure infliximab trough levels on the BÜHLMANN Quantum Blue® Platform.
BÜHLMANN Quantum Blue® fCAL – Calprotectin POC
A brief overview of BÜHLMANN Laboratories and their product portfolio as well as an introduction to Calprotectin measurement on BÜHLMANN’s Quantum Blue® fCAL assays.